PharmiWeb2h
ICON portfolio of AI tools drives clinical trial efficiencies
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced ...
PharmiWeb53m
Marinomed Biotech AG: Changes to the Management Board
PersonnelMarinomed Biotech AG: Changes to the Management Board 31.01.2025 / 12:10 CET/CESTThe issuer is solely responsible for the content of this announcement. Marinomed Biotech AG: Changes to the ...
PharmiWeb2h
RYSTIGGO® (rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods
UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...
PharmiWeb2h
Aston Institute for Membrane Excellence receives £500,000 grant from the Wolfson Foundation for state-of-the-art microscope
Aston Institute for Membrane Excellence (AIME) has received a £500,000 grant from the Wolfson Foundation to purchase an ultrafast confocal spinning disc microscope. This instrument will accelerate ...
PharmiWeb2h
BrightHeart Unveils Breakthrough AI Results at the…
BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, presented two groundbreaking studies during the oral plenary and concurrent sessions on ...
PharmiWeb2h
Amicus Therapeutics launches Amicus Ignite, a proactive community funding programme for initiatives that support people living with Pompe disease
Amicus Therapeutics UK Limited (Nasdaq: FOLD), a patient-dedicated biotechnology company, today announced the launch of Amicus Ignite, a proactive community funding programme to support initiatives ...
PharmiWeb2h
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...
PharmiWeb2h
European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced that the European Commission has authorised Vocabria (cabotegravir ...
PharmiWeb2h
Sarclisa is the first anti-CD38 treatment approved…
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...
PharmiWeb2h
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...
PharmiWeb2h
Abbott Showcases Latest Research and Technology to Advance Care for Chronic Pain Conditions at NANS
Abbott announced new four-year data showing the long-term and sustained relief that its proprietary BurstDR™ spinal cord stimulation (SCS) technology provides people with chronic pain, particularly ...
PharmiWeb2h
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...